Elanco Animal Health Inc. ELAN Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Elanco Animal Health Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Elanco Animal Health Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Elanco Animal Health Inc.'s business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Elanco Animal Health Inc.'s business segments — R&D?
- Elanco Animal Health Inc. (ELAN) reported business segments — R&D of $97M in Q1 2026.
- How has Elanco Animal Health Inc.'s business segments — R&D changed year-over-year?
- Elanco Animal Health Inc.'s business segments — R&D increased by 3.2% year-over-year, from $94M to $97M.
- What is the long-term trend for Elanco Animal Health Inc.'s business segments — R&D?
- Over 3 years (2022 to 2025), Elanco Animal Health Inc.'s business segments — R&D has grown at a 4.7% compound annual growth rate (CAGR), from $321M to $368M.
- What does business segments — R&D mean?
- Costs associated with developing new products and improving existing ones.
- How do you interpret business segments — R&D?
- Higher spending suggests a commitment to future innovation, though it may temporarily reduce current net income.
- How does business segments — R&D compare across companies?
- Standard R&D expense metric found in all R&D-intensive pharmaceutical companies.